Sheng Iris Y, Barata Pedro, Alameddine Raafat, Garcia Jorge A
Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Department of Internal Medicine, Section of Hematology Oncology, Tulane University Medical School, New Orleans, LA, USA.
Drugs Context. 2021 Mar 15;10. doi: 10.7573/dic.2020-10-2. eCollection 2021.
Significant changes in the management of patients with de novo metastatic prostate cancer have led to the use of novel oral agents and docetaxel-based chemotherapy earlier in the natural history of their disease. Our main challenge is the lack of prospective randomized data comparing these regimens. It is clear that treatment intensification is needed. Yet, the heterogeneity of this patient population coupled with the lack of understanding of the specific biology for a given individual makes treatment selection challenging. The aim of this narrative review is to discuss the importance of defining advanced disease by volume, the necessity for treatment intensification, and the current and future landscape of metastatic hormone-sensitive prostate cancer management.
新发转移性前列腺癌患者管理方面的重大变化，已导致在疾病自然史的早期就使用新型口服药物和基于多西他赛的化疗。我们面临的主要挑战是缺乏比较这些治疗方案的前瞻性随机数据。显然需要强化治疗。然而，该患者群体的异质性，再加上对特定个体具体生物学特性缺乏了解，使得治疗选择具有挑战性。本叙述性综述的目的是讨论按肿瘤体积定义晚期疾病的重要性、强化治疗的必要性，以及转移性激素敏感性前列腺癌管理的现状和未来前景。
